Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol

CONCLUSION: While in cohort A pembrolizumab lacked activity, cohort B and cohort C met the study's primary endpoint. Further research is warranted to refine selection of patients with tumors harboring lower TMLs and may benefit from a focus on innate immunity.PMID:38630551 | DOI:10.1158/1078-0432.CCR-24-0011

Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Birgit S Geurts Laurien J Zeverijn Lindsay V M Leek Jade M van Berge Henegouwen Louisa R Hoes Hanneke van der Wijngaart Vincent van der Noort Joris van de Haar Annemiek van Ommen-Nijhof Marleen Kok Paul Roepman Anne M L Jansen Wendy W J de Leng Maja J A d Source Type: research